(ARWR) Arrowhead Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 9.274m USD | Total Return: 440.4% in 12m

RNAi, Hepatic, Metabolic, Cardiovascular, Rare
Total Rating 66
Safety 29
Buy Signal 0.24
Biotechnology
Industry Rotation: -2.5
Market Cap: 9.27B
Avg Turnover: 109M USD
ATR: 4.93%
Peers RS (IBD): 87.3
Risk 5d forecast
Volatility70.3%
Rel. Tail Risk-10.6%
Reward TTM
Sharpe Ratio2.88
Alpha438.20
Character TTM
Beta1.950
Beta Downside2.580
Drawdowns 3y
Max DD75.86%
CAGR/Max DD0.40
EPS (Earnings per Share) EPS (Earnings per Share) of ARWR over the last years for every Quarter: "2021-03": -0.26, "2021-06": -0.29, "2021-09": -0.61, "2021-12": -0.6, "2022-03": 0.41, "2022-06": -0.68, "2022-09": -0.81, "2022-12": -0.39, "2023-03": 0.45, "2023-06": -0.96, "2023-09": -1.02, "2023-12": -1.24, "2024-03": -1.02, "2024-06": -1.38, "2024-09": -1.37, "2024-12": -1.39, "2025-03": 2.75, "2025-06": -1.26, "2025-09": -0.11, "2025-12": 0.22,
EPS CAGR: -15.30%
EPS Trend: 6.0%
Last SUE: 0.08
Qual. Beats: 0
Revenue Revenue of ARWR over the last years for every Quarter: 2021-03: 32.811, 2021-06: 45.891, 2021-09: 38.283, 2021-12: 27.439, 2022-03: 151.805, 2022-06: 32.412, 2022-09: 31.575, 2022-12: 62.546, 2023-03: 146.267, 2023-06: 15.825, 2023-09: 16.097, 2023-12: 3.551, 2024-03: 0, 2024-06: 0, 2024-09: 23.589, 2024-12: 2.5, 2025-03: 542.709, 2025-06: 27.767, 2025-09: 256.472, 2025-12: 264.033,
Rev. CAGR: 15.90%
Rev. Trend: 4.8%
Last SUE: 0.20
Qual. Beats: 0

Warnings

Beneish M-Score 1.00 > -1.5 - likely earnings manipulation

Altman Z'' 0.31 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: ARWR Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (NASDAQ: ARWR) focuses on RNA-interference (RNAi) therapeutics targeting genes that drive hard-to-treat metabolic and cardiovascular diseases. Its lead pipeline features Plozasiran (apoC-III) and Zodasiran (ANGPTL3), both in Phase 3 trials, alongside a suite of early-stage RNAi candidates (ARO-DIMER-PA, ARO-PNPLA3, ARO-INHBE, ARO-ALK7, ARO-RAGE, ARO-MAPT, ARO-C3, ARO-CFB) in Phase 1/2a studies. The company leverages collaborations with GSK, Takeda, Amgen and Sarepta to expand development and commercialization capabilities.

As of the latest Q4 2025 filing, Arrowhead reported $210 million of cash and marketable securities, giving it roughly an 18-month runway at current burn rates. In July 2025, the Plozasiran Phase 3 trial achieved its primary endpoint, showing a 45 % reduction in triglycerides versus placebo, while the Zodasiran trial is on track for readout in early 2026. The RNAi sector is experiencing strong tailwinds, with analysts projecting a 13 % CAGR through 2030 driven by growing FDA approvals and expanding payer acceptance for gene-silencing therapies.

For a deeper dive into ARWR’s valuation metrics, you might explore ValueRay’s analyst tools.

Headlines to Watch Out For
  • RNAi drug pipeline advancements drive investor optimism
  • Clinical trial results for ARO-APOC3 impact stock volatility
  • Royalty revenue from Takeda collaboration boosts financials
  • Regulatory approval for new drug candidates accelerates growth
  • Research and development expenses influence profitability
Piotroski VR‑10 (Strict) 6.0
Net Income: 202.3m TTM > 0 and > 6% of Revenue
FCF/TA: 0.20 > 0.02 and ΔFCF/TA 76.46 > 1.0
NWC/Revenue: 75.80% < 20% (prev 1.83k%; Δ -1.75k% < -1%)
CFO/TA 0.21 > 3% & CFO 339.3m > Net Income 202.3m
Net Debt (-603.8m) to EBITDA (370.2m): -1.63 < 3
Current Ratio: 3.38 > 1.5 & < 3
Outstanding Shares: last quarter (140.7m) vs 12m ago 12.70% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 83.35% > 50% (prev 2.57%; Δ 80.77% > 0%)
Interest Coverage Ratio: 3.83 > 6 (EBITDA TTM 370.2m / Interest Expense TTM 90.2m)
Altman Z'' 0.31
A: 0.52 (Total Current Assets 1.17b - Total Current Liabilities 347.4m) / Total Assets 1.60b
B: -1.00 (Retained Earnings -1.60b / Total Assets 1.60b)
C: 0.26 (EBIT TTM 345.1m / Avg Total Assets 1.31b)
D: -1.53 (Book Value of Equity -1.59b / Total Liabilities 1.04b)
Altman-Z'' Score: 0.31 = B
Beneish M 1.00
DSRI: 2.09 (Receivables 218.9m/2.50m, Revenue 1.09b/26.1m)
GMI: 0.26 (GM 97.70% / 25.00%)
AQI: 0.44 (AQ_t 0.00 / AQ_t-1 0.01)
SGI: 41.82 (Revenue 1.09b / 26.1m)
TATA: -0.09 (NI 202.3m - CFO 339.3m) / TA 1.60b)
Beneish M-Score: 26.05 (Cap -4..+1) = D
What is the price of ARWR shares? As of April 15, 2026, the stock is trading at USD 66.69 with a total of 1,299,271 shares traded.
Over the past week, the price has changed by +9.01%, over one month by +16.25%, over three months by +1.18% and over the past year by +440.44%.
Is ARWR a buy, sell or hold? Arrowhead Pharmaceuticals has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy ARWR.
  • StrongBuy: 7
  • Buy: 3
  • Hold: 5
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ARWR price?
Analysts Target Price 81.1 21.6%
Arrowhead Pharmaceuticals (ARWR) - Fundamental Data Overview as of 11 April 2026
P/E Trailing = 41.3938
P/E Forward = 97.0874
P/S = 8.5009
P/B = 15.0411
P/EG = -1.32
Revenue TTM = 1.09b USD
EBIT TTM = 345.1m USD
EBITDA TTM = 370.2m USD
Long Term Debt = 163.1m USD (from longTermDebt, last quarter)
Short Term Debt = 47.5m USD (from shortTermDebt, last quarter)
Debt = 312.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -603.8m USD (recalculated: Debt 312.8m - CCE 916.6m)
Enterprise Value = 8.67b USD (9.27b + Debt 312.8m - CCE 916.6m)
Interest Coverage Ratio = 3.83 (Ebit TTM 345.1m / Interest Expense TTM 90.2m)
EV/FCF = 26.93x (Enterprise Value 8.67b / FCF TTM 322.0m)
FCF Yield = 3.71% (FCF TTM 322.0m / Enterprise Value 8.67b)
FCF Margin = 29.52% (FCF TTM 322.0m / Revenue TTM 1.09b)
Net Margin = 18.54% (Net Income TTM 202.3m / Revenue TTM 1.09b)
 Gross Margin = unknown ((Revenue TTM 1.09b - Cost of Revenue TTM 25.1m) / Revenue TTM)
 Tobins Q-Ratio = 5.40 (Enterprise Value 8.67b / Total Assets 1.60b)
Interest Expense / Debt = 7.20% (Interest Expense 22.5m / Debt 312.8m)
Taxrate = 0.10% (29.0k / 28.3m)
NOPAT = 344.8m (EBIT 345.1m * (1 - 0.10%))
Current Ratio = 3.38 (Total Current Assets 1.17b / Total Current Liabilities 347.4m)
Debt / Equity = 0.55 (Debt 312.8m / totalStockholderEquity, last quarter 568.4m)
Debt / EBITDA = -1.63 (Net Debt -603.8m / EBITDA 370.2m)
Debt / FCF = -1.88 (Net Debt -603.8m / FCF TTM 322.0m)
Total Stockholder Equity = 560.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.45% (Net Income 202.3m / Total Assets 1.60b)
RoE = 36.12% (Net Income TTM 202.3m / Total Stockholder Equity 560.0m)
RoCE = 47.73% (EBIT 345.1m / Capital Employed (Equity 560.0m + L.T.Debt 163.1m))
RoIC = 42.93% (NOPAT 344.8m / Invested Capital 803.1m)
WACC = 12.66% (E(9.27b)/V(9.59b) * Re(12.84%) + D(312.8m)/V(9.59b) * Rd(7.20%) * (1-Tc(0.00)))
Discount Rate = 12.84% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.45%
[DCF] Terminal Value 67.90% ; FCFF base≈322.0m ; Y1≈397.2m ; Y5≈677.8m
[DCF] Fair Price = 46.22 (EV 5.87b - Net Debt -603.8m = Equity 6.47b / Shares 140.0m; r=12.66% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 6.01 | EPS CAGR: -15.30% | SUE: 0.08 | # QB: 0
Revenue Correlation: 4.81 | Revenue CAGR: 15.90% | SUE: 0.20 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.37 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=10
EPS current Year (2026-09-30): EPS=-3.24 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+2 | Growth EPS=-32290.9% | Growth Revenue=-46.0%
EPS next Year (2027-09-30): EPS=-4.30 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=-32.7% | Growth Revenue=-29.3%
[Analyst] Revisions Ratio: -0.14 (3 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 10.4% (Discount Rate 12.8% - Earnings Yield 2.4%)
[Growth] Growth Spread = +4.0% (Analyst 14.5% - Implied 10.4%)
External Resources
Dataroma Stockcircle